The myelodysplastic syndromes (MDS) are clonal haematopoietic disorders that develop de novo and also secondary to chemotherapy and/or radiation therapy. We previously demonstrated that the risk of MDS is increased among atomic bomb survivors with significant correlation to radiation dose; however, the clinical characteristics of these survivors have not been well analysed. In this study, we investigated chromosomal abnormalities of MDS among survivors. The frequency of abnormal karyotypes was significantly higher, with more very poor risk karyotypes, according to the revised International Prognostic Scoring System, among those exposed close to the hypocentre compared with unexposed cases. However, abnormal karyotype frequency did not reflect the prognosis of exposed cases with respect to distance from the hypocentre. In addition, there was no difference in prognosis between exposed and unexposed cases. Among proximally exposed cases (<1Á5 km from the hypocentre), chromosomal translocations and inversions were more frequent, and the frequency of structural alterations in chromosomes 3, 8, and 11 was significantly increased compared with unexposed cases. These results suggest that chromosomal alterations in MDS among survivors have different features compared with those in de novo or therapy-related MDS. Detailed molecular study is warranted.
Summary
The myelodysplastic syndromes (MDS) are clonal haematopoietic disorders that develop de novo and also secondary to chemotherapy and/or radiation therapy. We previously demonstrated that the risk of MDS is increased among atomic bomb survivors with significant correlation to radiation dose; however, the clinical characteristics of these survivors have not been well analysed. In this study, we investigated chromosomal abnormalities of MDS among survivors. The frequency of abnormal karyotypes was significantly higher, with more very poor risk karyotypes, according to the revised International Prognostic Scoring System, among those exposed close to the hypocentre compared with unexposed cases. However, abnormal karyotype frequency did not reflect the prognosis of exposed cases with respect to distance from the hypocentre. In addition, there was no difference in prognosis between exposed and unexposed cases. Among proximally exposed cases (<1Á5 km from the hypocentre), chromosomal translocations and inversions were more frequent, and the frequency of structural alterations in chromosomes 3, 8, and 11 was significantly increased compared with unexposed cases. These results suggest that chromosomal alterations in MDS among survivors have different features compared with those in de novo or therapy-related MDS. Detailed molecular study is warranted.
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The myelodysplastic syndromes (MDS) are clonal haematopoietic stem cell disorders characterized by morphological dysplasia, ineffective haematopoiesis, and transformation to acute myeloid leukaemia (AML) (Tefferi & Vardiman, 2009) , carrying various mutated genes and pathways in almost all cases (Bejar et al, 2011; Haferlach et al, 2014) . In general, 40-60% of MDS patients display clonal chromosomal abnormalities; most are unbalanced alterations, such as chromosome loss, deletions or gain; balanced abnormalities, such as translocations, are rare (Haase et al, 2007) . In the recently revised International Prognostic Scoring System (IPSS-R) , karyotype was the most influential prognostic parameter for overall survival (OS) as well as leukaemia-free survival (LFS), which was confirmed by Spanish and German groups Valc arcel et al, 2013) , emphasizing its importance. MDS arise de novo or are therapy-related. The outcome of patients with therapy-related MDS (T-MDS) is poorer than that of de novo MDS, and cytogenetic features in the two groups are partially different from each other (Mauritzson et al, 2002; Smith et al, 2003) . Ionizing radiation induces chromosomal and genetic abnormalities, and our retrospective cohort study of Nagasaki Atomic Bomb (A-bomb) survivors revealed that acute radiation exposure is associated with an increased risk of developing MDS, even 40-60 years after the exposure (Iwanaga et al, 2011) . However, subsequent analyses failed to demonstrate a significant difference in survival or transformation to leukaemia with respect to distance from the hypocentre, even though a higher frequency of complex karyotypes is observed among proximally exposed cases (Iwanaga et al, 2011; Matsuo et al, 2016) . This raised questions regarding the effect of A-bomb radiation on chromosome aberrations and its clinical meaning in MDS, and prompted us to further investigate chromosomal abnormalities and their impact on survival and leukaemia transformation in MDS among survivors in more detail.
Materials and methods

Patients
We collected clinical information of MDS patients diagnosed from 1985 to 2013 registered in the Nagasaki-City MDS database (Iwanaga et al, 2011; Matsuo et al, 2016) . This database includes information from five hospitals in Nagasaki city. Selected results, using the database, regarding the association between MDS risk and A-bomb radiation exposure and survival have been published previously (Iwanaga et al, 2011; Matsuo et al, 2016) . Patients were diagnosed according to the French-American-British (FAB) classification criteria (Bennett et al, 1982) , and their risk was evaluated using the IPSS (Greenberg et al, 1997) and IPSS-R . In this analysis, we excluded patients less than 40 years old, because the youngest cases exposed to A-bomb radiation were aged 40 years in 1985. Patients that received chemo and / or radiation therapy before the diagnosis of MDS, or who lacked successful cytogenetic data were likewise excluded. We defined A-bomb survivors as those who were present within 10 km of the hypocentre at the time of the bombing with known exposure distance. Patients were followed until June 2015. The study was conducted in accordance with the modified declaration of Helsinki, and approved by the ethic committees of the participating hospitals.
Bone marrow morphology and blood cell counts
Bone marrow morphology and blood cell count examinations were performed locally at each hospital and reviewed centrally. For clarity, MDS (and transformation to leukaemia) was classified according to the FAB classification only, because cases diagnosed before the 2001 World Health Organization (WHO) classification were included.
Therapy
Patients received several treatments at each institution, including supportive care with blood transfusions, antibiotics, iron chelation and haematopoietic growth factors, chemotherapies, immunosuppressive agents and hypomethylating agents. Seven out of 133 exposed cases (5Á3%; see below, shown in Table I ), and 32 out of 269 unexposed cases (11Á9%) were treated with hypomethylating agent. We excluded patients that underwent haematopoietic stem cell transplantation because no A-bomb survivors underwent such transplant therapy.
Cytogenetic examination
Cytogenetic analysis was performed using a conventional Gbanding technique at the time of first diagnosis. Cytogenetic analysis of bone marrow samples was performed at the individual centres and the results were reviewed centrally. Karyotypes were documented according to the International System for Cytogenetic Nomenclature (ISCN) recommendations (Shaffer et al, 2009) . The median number of metaphases in the entire cohort was 20 and ranged from 4 to 50. Only one patient had less than 10 metaphases. Results from fluorescent in situ hybridization (FISH) without conventional G-banding were excluded, and no case was shown to have normal karyotype using FISH only. The number of abnormalities was calculated according to international guidelines (Chun et al, 2010) . A missing chromosome was classified as monosomy; an additional chromosome as trisomy; deletions as structural losses; additions, insertions and duplications as structural gains; and balanced translocations and inversions as structurally neutral changes (Schanz et al, 2013) .
Statistical analysis
To clarify the influence of the radiation, we categorized patients into four groups according to exposure status (exposure distance: <1Á5 km, 1Á5-2Á99 km, ≥3 km in the 10-km catchment area, and unexposed patients). The estimated dose of gamma radiation was about 1 Gy at 1Á5 km, and 5 mGy at 3 km from the hypocentre according to the dosimetry system 2002, and corresponding distance categories were applied in our previous studies (Young & Kerr, 2005; Iwanaga et al, 2011) . The estimated excess relative risk of MDS among survivors was 4Á3/Gy (Iwanaga et al, 2011) . Independent groups were compared using the chi-square test and Fisher's exact test. Univariate time-to-event analyses were calculated with the method of Kaplan and Meier Table I . Clinical characteristics of patients. A-bomb survivors (total and subgroups by distance from hypocentre) 
IPSS-R, revised International Prognostic Scoring System. (1958). OS was calculated from time of first diagnosis to death or last contact, and LFS from time of diagnosis to transformation to leukaemia, or last contact without transformation. P-values for differences in time-to-event analysis were calculated by the log-rank test (Peto et al, 1977) . Tests of significance were two sided, and P < 0Á05 were considered statistically significant. Statistical analyses were performed with Prism Version 5.0 software (GraphPad Software Inc., La Jolla, CA, USA) and EZR (Kanda, 2013) .
Results
Patients
In the database, 402 patients were cytogenetically evaluable; 133 patients were A-bomb survivors and 269 were unexposed. Among survivors, the number of cases according to distance from the hypocentre was 29 in the <1Á5 km group (Group I), 35 in the 1Á5-2Á99 km group (Group II) and 69 in the ≥3 km group (Group III). The median follow-up time was 27 (0-330) months. In Group I, no patients were treated with DNA hypomethylating agents. Patients' characteristics are summarized in Table I . There were no statistical differences in age, gender, FAB classification or the percentage of blasts in bone marrow among groups. In terms of cytopenia, the median platelet count in Group I was higher than that in the other groups. The IPSS-R risk could not be calculated in 12 cases in the unexposed group, because some haematological data were not available. Prognostic risk stratification according to IPSS and IPSS-R, showed that patients in Group I tended to be stratified by IPSS as "High risk" and by IPSS-R as "Very High risk". Table II summarizes karyotype and IPSS-R cytogenetic risk category data among cases. Comparing all A-bomb survivors and unexposed cases, there was no significant difference in the distribution of cases in each risk category. However, comparison among groups by distance from the hypocentre showed that the frequency of abnormal karyotypes was significantly higher in Group I than in the other groups (P = 0Á006, Table II ). There was also a significant difference in the distribution of IPSS-R cytogenetic risk among all groups (P = 0Á009, Table II) , with the highest frequency of "Very poor karyotype" in Group I. In the Intermediate cytogenetic risk category, the frequency of "any other independent clone" was the highest in Group I. In the Very poor cytogenetic risk group, the number of patients with extremely complex abnormalities (the number of aberrations ≥8) differed significantly among groups (27Á6% in Group I, 0% in Group II, 1Á4% in Group III and 4Á5% in the unexposed group, P < 0Á001, Table II ). There was no statistical difference in OS or LFS between all A-bomb survivors and unexposed cases (OS: Fig 1A , P = 0Á731; LFS: Fig 1B, P = 0Á294 ).
IPSS-R cytogenetic risk category and survival difference
As we reported previously (Matsuo et al, 2016) , there was no statistical difference in either OS or LFS among Groups I, II and III (data not shown).
Detailed cytogenetic analysis in Group I
In general, it is assumed that those who were closer to the hypocentre received higher doses of A-bomb radiation, resulting in higher risk of haematological neoplasms. This was shown in our pervious report regarding the risk of MDS among survivors (Iwanaga et al, 2011) . To better understand the effects of A-bomb radiation on chromosome aberration, we compared in detail the cytogenetic abnormalities between Group I and unexposed cases (Table III) . The most frequent type of chromosomal aberration in Group I was deletions (Del, 13 out of 21 cases, 61Á9%), followed by structural gain (St-gain, 11 cases, 52Á4%), structurally neutral changes (St-neu, 10 cases, 47Á6%), monosomy (7 cases, 33Á3%) and trisomy (5 cases, 23Á8%). St-neu, which included random balanced translocations and inversions, was detected in 10 out of 21 cases (47Á6%) without specific breakpoints, which was a significantly higher portion compared with the unexposed group (12 out of 123 cases, 9Á7%, P < 0Á001). We next focused on individual chromosomes to see whether alterations were accumulated in specific chromosomes in Group I cases (Fig 2) . Although monosomy of chromosomes 5 and 7 were observed in Group I, their frequency was not different from that in the unexposed group (Fig 2A) . Among trisomic changes, trisomy of chromosome 8 showed the highest frequency in both Group I and the unexposed group without statistically significant difference (Fig 2A) . Chromosome 1 was more often involved with Del in Group I than in the unexposed group (P = 0Á01), and the incidence of Del in chromosomes 5 and 20 was equally high in both Group I and the unexposed group (Fig 2B) . St-gain in chromosome 11 was significantly increased in Group I (P = 0Á002, Fig 2B) . The involvement of 11q23 or -pecific abnormalities was rare. Analysis of the structural alterations of each chromosome, combining St-gain, Del and St-neu changes but excluding monosomy and trisomy (Fig 3) , showed that chromosome 11 was affected in seven out of 21 cases (33Á3%) in Group I, which was significantly more frequent compared with the unexposed group (six out of 123 cases, 4Á9%) (P = 0Á001). Chromosomes 3 and 8 were also affected significantly more often in Group I (six and three out of 21 cases, respectively) than in the unexposed group (eight and one out of 123 cases, respectively, P = 0Á007, and 0Á01, respectively), with 3q27 being involved in three cases. In Group I, there were two cases each with the following abnormalities: random translocation involving 3q, monosomy 9 and monosomy X.
Effect of cytogenetic abnormalities on survival in Group I
To better investigate the impact of cytogenetic alterations on OS among A-bomb survivors, a survival curve was estimated using the Kaplan-Meier method. As shown in Fig 4A, B , IPSS-R cytogenetic risk category was a statistically significant factor for OS for both total survivors (P < 0Á001) and unexposed cases (P < 0Á001). It also had a significant impact on OS in Group I (P = 0Á015, Figure S1 ). The number of chromosomal alterations in each case showed significant impact on OS for both survivors and unexposed cases (P < 0Á001 for both, Figure S2A , B). Those who had eight or more aberrations had a similar survival rate to those with 4-7 aberrations among unexposed cases (Figure S2B) . In MDS of survivors, those with eight or more aberrations showed no difference in survival rate (P = 0Á162) compared to those with 4-7 aberrations (black solid line and black broken line, Figure S2A ). However, cases in Group I with "Very Poor" cytogenetic abnormalities had a significantly better OS compared with that of the unexposed group (P = 0Á008, Fig 5A) . Because all Group I cases with "Very poor" cytogenetic abnormalities had eight or more chromosomal alterations, we compared the OS of cases with eight or more alterations between Group I and the unexposed group. The survival was better in Group I than in the unexposed group among these restricted cases (P = 0Á01, Fig 5B) . Most of these Group I cases contained balanced translocations.
Discussion
In this study, we demonstrated the importance of the karyotype as a prognostic factor for patients with MDS among A-bomb survivors. The cytogenetic risk categories of the IPSS-R could stratify both exposed and unexposed MDS cases, confirming the universal significance of cytogenetics as a predicting factor for both OS and LFS in MDS. Interestingly, however, the number of chromosomal alterations did not show the same power for exposed and unexposed cases. Among complex karyotypes, the highly complex alterations, especially eight or more alterations, predicted a poorer prognosis among unexposed cases (de novo MDS), as expected. However, A-bomb survivors with eight or more alterations showed no difference in survival from those with four to seven abnormalities. This could be attributable, at least in part, to the significantly higher portion of copy number neutral chromosomal alterations, such as translocations and inversions, in MDS of survivors, which would also partly explain the high incidence of abnormal karyotype in Group I. It is well known that ionizing radiation causes DNA double strand breaks, and that balanced chromosomal translocations are generated as a result (Bender et al, 1988) . It was reported that some long-term A-bomb survivors have chromosomal alterations, usually translocations, in haematopoietic cells as a stable chromosomal change, in particular among those exposed proximally (Amenomori et al, 1988) . In this regard, some chromosomal abnormalities among survivors might contain stable translocations generated by Abomb radiation with presumably low or no leukaemogenic impact. This may be one of the reasons why there was no survival difference between exposed and unexposed cases in spite of the increased number of cytogenetic changes among survivors.
Another interesting finding was the accumulation of abnormalities on chromosomes 3, 8 and 11 in MDS among survivors. Among haematological malignancies, therapyrelated chromosomal changes after administration of topoisomerase II inhibitors (TOPO-II-ih) affects chromosome 11q23 as a hot spot (Domer et al, 1995; Leone et al, 2007) ; therefore, we thought A-bomb radiation could work as a TOPO-II-ih. However, 11q23 was not a recurrent alteration site, and other sites on chromosome 11 were also affected. As shown in Figure 3 , in A-bomb survivors, chromosome 11 was involved in seven out of 21 cases with chromosomal abnormalities, which was significantly higher than the rate for unexposed cases; two of them had a breakpoint at 11q23, three at 11q13, and the breakpoints in the other two were located in the short arm of chromosome 11. For chromosome 3, 3q27 was affected in three out of six cases. Considering the size of chromosomes, and the random manner of DNA damage by ionizing radiation, chromosome 1 has the highest probability of being affected; however, our data does not support this hypothesis. It is suggested that a selection advantage existed for haematopoietic cells that obtained chromosome 3 and/or 11 abnormalities after exposure to radiation. Molecular studies will address these questions.
In this study, the number of MDS cases among survivors was not sufficient to establish new cytogenetic risk categories, and this also contributed to the low power of the study. Considering the length of time between the explosion (1945) and when we recognized MDS among survivors around 1980, it was difficult to collect large numbers of MDS cases among survivors, but we could confirm the usefulness of IPSS-R cytogenetic risk categories and the IPSS-R score itself to predict survival for exposed cases. Clinically, we can apply these systems to MDS among survivors.
After chemotherapy and/or radiation therapy for malignancies e.g. breast cancer, the incidence of MDS increases (Malmgren et al, 2016) , i.e., T-MDS. A high frequency of abnormal karyotypes, especially complex karyotypes and unbalanced abnormalities of chromosomes 5, 7 and 17, are well known features induced by alkylating agents, and the 11q23 locus is frequently affected by TOPO-II-ih treatment (Mauritzson et al, 2002; Smith et al, 2003) . As the exposure to A-bomb radiation is the major difference between survivors and de novo cases, it was assumed that MDS among survivors might have features similar to T-MDS. However, there was no apparent similarity between T-MDS and MDS among survivors in this study. First, we did not observe a significant difference in survival between exposed and unexposed groups. Second, although the frequency of abnormal karyotypes is high in proximally exposed cases, the karyotype abnormalities per se did not show a clear similarity to those of T-MDS. It seems that detailed studies of MDS among survivors, such as molecular-based investigations, are necessary, and could provide further important answers to these questions.
